UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Ear Drops for Children With Otitis Media

Not Applicable

Completed

Conditions: Acute Otitis Media

Interventions: Drug: Hyland's earache drops

First Posted Date: 2008-02-25

Last Posted Date: 2010-12-02

Lead Sponsor: University of Washington

Target Recruit Count: 119

Registration Number: NCT00622518

Locations: 🇺🇸
University of Washington Medical Center-Roosevelt Pediatric Care Center, Seattle, Washington, United States

Management of Pain in Persons With Multiple Sclerosis

Not Applicable

Completed

Conditions: Multiple Sclerosis
Pain

Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)
Behavioral: Cognitive Behavioral Therapy (CBT)
Behavioral: Self-Hypnosis Training (HYP)
Behavioral: Education Control (CONT)

First Posted Date: 2008-02-22

Last Posted Date: 2013-01-16

Lead Sponsor: University of Washington

Target Recruit Count: 22

Registration Number: NCT00621374

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

Phase 1

Completed

Conditions: Adverse Drug Interactions

Interventions: Dietary Supplement: sulforaphane plus rifampicin
Drug: Rifampicin
Dietary Supplement: sulforaphane alone

First Posted Date: 2008-02-22

Last Posted Date: 2019-09-06

Lead Sponsor: University of Washington

Target Recruit Count: 29

Registration Number: NCT00621309

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
UW General Clinical Research Center, Seattle, Washington, United States

Adolescent Trauma Recovery and Stress Disorders Collaborative Care (ATRSCC) Model Program Trial

Not Applicable

Completed

Conditions: Alcohol Abuse
Alcohol Dependence
Post-traumatic Stress Disorder

Interventions: Behavioral: Adolescent Trauma Support Program

First Posted Date: 2008-02-20

Last Posted Date: 2018-02-19

Lead Sponsor: University of Washington

Target Recruit Count: 120

Registration Number: NCT00619255

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States

A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain

Phase 4

Completed

Conditions: Osteoarthritis
Pain

Interventions: Drug: Venlafaxine

First Posted Date: 2008-02-11

Last Posted Date: 2008-02-11

Lead Sponsor: University of Washington

Target Recruit Count: 18

Registration Number: NCT00611676

Perioperative Therapy for Resectable Pancreatic Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Pancreas
Stage IA Pancreatic Cancer
Stage IB Pancreatic Cancer
Stage IIA Pancreatic Cancer
Stage IIB Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: docetaxel
Drug: capecitabine
Radiation: intensity-modulated radiation therapy
Drug: oxaliplatin
Procedure: pancreatic surgical procedure
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2008-02-07

Last Posted Date: 2017-07-13

Lead Sponsor: University of Washington

Target Recruit Count: 35

Registration Number: NCT00609336

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Computer Assisted Relaxation Learning for Dental Offices

Not Applicable

Completed

Conditions: Dental Anxiety

Interventions: Behavioral: Computer Assisted Relaxation Learning
Behavioral: Pamphlet

First Posted Date: 2008-02-07

Last Posted Date: 2013-02-20

Lead Sponsor: University of Washington

Target Recruit Count: 84

Registration Number: NCT00609648

Locations: 🇺🇸
Dr. Gary Templeman, DDS, Corvallis, Oregon, United States
🇺🇸
Michael C Hazel, DMD, PC, West Linn, Oregon, United States
🇺🇸
Northwest Dental Fears Research, Bremerton, Washington, United States

and more 2 locations

A Single-Blind Placebo Run-in Study of Duloxetine for Activity-Limiting Osteoarthritis Pain

Phase 4

Completed

Conditions: Osteoarthritis
Pain

Interventions: Drug: duloxetine

First Posted Date: 2008-02-07

Last Posted Date: 2008-02-07

Lead Sponsor: University of Washington

Target Recruit Count: 25

Registration Number: NCT00609557

Disseminating Organizational SBI Services at Trauma Centers

Not Applicable

Completed

Conditions: Alcohol Dependence
Alcohol Abuse

Interventions: Behavioral: Brief Intervention

First Posted Date: 2008-02-06

Last Posted Date: 2018-03-07

Lead Sponsor: University of Washington

Target Recruit Count: 878

Registration Number: NCT00607620

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma

Interventions: Drug: vorinostat
Biological: rituximab
Drug: ifosfamide
Drug: carboplatin
Drug: etoposide
Other: pharmacological study
Other: laboratory biomarker analysis
Genetic: gene expression analysis

First Posted Date: 2008-01-28

Last Posted Date: 2017-05-25

Lead Sponsor: University of Washington

Target Recruit Count: 29

Registration Number: NCT00601718

Locations: 🇺🇸
Puget Sound Oncology Consortium, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy